Тиотропия бромид: новые данные об эффективности препарата при обструктивных заболеваниях легких

1. Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. The 2011 report is available on www.goldcopd.com
2. Panning CA, DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 2003; 23: 183–9.
3. Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin Pulm Med 2010; 16: 97–105.
4. Donohue JF, van Noord JA, Bateman ED et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55.
5. Vincken W, van Noord JA, Greefhorst APM et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotopium. Eur Respir J 2002; 19: 209–16.
6. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 1: 217–24.
7. Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404.
8. Celli B, Wallack RZ, Wang S et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743–8.
9. O'Donnell DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832–48.
10. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–54.
11. Decramer M, Celli B, Kesten S et al. for the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171–8.
12. Troosters T, Celli B, Lystig T et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010; 36: 65–73.
13. Morice AH, Celli B, Kesten S et al. COPD in young patients: A pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med 2010; 104: 1659–67.
14. van Noord JA, Aumann JL, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214–22.
15. Baloira Villar A, Vilariño Pombo C. Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease. Arch Bronconeumol 2005; 41: 130–4.
16. Vogelmeier C, Kardos P, Harari S et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008; 102: 1511–20.
17. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134: 255–62.
18. Mahler DA, D’Urzo A, Bateman ED et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012; 67: 781–8.
19. Aalbers R, Maleki-Yazdi MR, Hamilton A et al. Dose-finding study for tiotropium and olodaterol when administered in combination via the RespimatR inhaler in patients with COPD. Proceedings of ERS Annual Congress, Vienna, 2012: p. 2882.
20. van Noord JA, Smeets JJ, Drenth BM et al. 24-hour bronchodilation following a single dose of the novel b(2)-agonist olodaterol in COPD. Pulm Pharmacol Ther 2011; 24: 666–72.
21. Bouyssou T, Casarosa P, Naline E et al. Pharmacological Characterization of Olodaterol, a Novel Inhaled b2-Adrenoceptor Agonist Exerting a 24-Hour-Long Duration of Action in Preclinical Models. JPET 2010; 334: 53–62.
22. Maltais F, Beck E, Webster D et al. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients. Eur Respir J 2010; 36 (Suppl. 54): 5557.
23. Short PM, Williamson PA, Elder DHJ et al. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting b-agonist therapy in COPD. Chest 2012; 141: 81–6.
24. Criner GJ, Scharf SM, Falk JA. National Emphysema Treatment Trial Research Group et al. Effect of lung volume reduction surgery on resting pulmonary hemodynamics in severe emphysema. Am J Respir Crit Care Med 2007; 176: 253–60.
25. Jörgensen K, Houltz E, Westfelt U et al. Effects of lung volume reduction surgery on left ventricular diastolic filling and dimensions in patients with severe emphysema. Chest 2003; 124: 1863–70.
26. Donaldson GC, Wedzicha JA. COPD exacerbations: epidemiology. Thorax 2006; 61: 164–8.
27. Briggs DD Jr, Covelli H, Lapidus R et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005; 18: 397–404.
28. Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093–103.
29. Koegler H, Rabe KF, Beeh KM et al. Association of b2-adrenoreceptor genotypes with prevention of COPD exacerbations by tiotropium or salmeterol in the POET-COPDR trial. Proceedings of ERS Annual Congress, Vienna, 2012: p. 2879.
30. Turki J, Pak J, Green SA et al. Genetic polymorphisms of the b2-adrenergic receptor in noctural and non-noctural asthma. Evidence t hat Gly 16 correlated with the noctural phenotype. J Clin Invest 1995; 95: 1635–41.
31. Liggett SB. Polymorphisms of the b2-adrenergic receptor and asthma. Am J Respir Crit Care Med 1997; 156: 156–62.
32. Reihsaus E, Innis M, Liggett SB. Mutations in the gene encoding for the b2-adrenoreceptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8: 334–9.
33. Ulbrecht M, Hergeth MK, Wist M. Association of b2-adrenoreceptor variants with bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000; 161: 469–74.
34. Kim SH, Oh HB, Oh SI. Association of b2-adrenoreceptor polymorphism with noctural cough among atopic subjects but not with atopy and nonspecific BHR. J Allergy Clin Immunol. 2002; 109: 630–5.
35. Peters SP, Kunselman SJ, Icitovic N et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363: 1715–26.
36. Kerstjens HAM, Engel M, Dahl R et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198–207.

С.Н.Авдеев

ФГБУ НИИ пульмонологии ФМБА России